Hester Biosciences Ltd.

NSE: HESTERBIO | BSE: 524669 | ISIN: INE782E01017 | Industry: Pharmaceuticals
| Mid-range Performer

1872.50
1.05%
ICICI Securities Limited
Despite exports being impacted by air shipment restrictions due to Covid, Hester ended FY21 on a relatively strong note amid strong demand for poultry vaccines and health products in domestic market. Going ahead, opportunities panning out from animal vaccines such as classical swine fever, lumpy skin disease (only player) and sheep pox (only player) in the domestic space besides increased focus on health products, growth prospects look promising for Hester. Additionally, the management intends to move away from preventive healthcare to curative healthcare as a long...
Hester Biosciences Ltd. is trading below its 200 day SMA of 2014.0
More from Hester Biosciences Ltd.
Recommended